argenx SE

315.32+4.77+1.54%Vol 53.20K1Y Perf 28.71%
Sep 23rd, 2021 12:49 DELAYED
BID314.85 ASK315.63
Open319.39 Previous Close310.55
Pre-Market- After-Market-
 - -%  - -
Target Price
363.00 
Analyst Rating
Strong Buy 1.21
Potential %
14.71 
Finscreener Ranking
★★★★★     63.09
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     55.78
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     59.99
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
53.45 
Earnings Rating
Neutral
Market Cap16.22B 
Earnings Date
28th Oct 2021
Alpha0.06 Standard Deviation0.18
Beta0.91 

Today's Price Range

315.32319.97

52W Range

238.58382.15

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-4.03%
1 Month
-6.01%
3 Months
-0.51%
6 Months
5.44%
1 Year
28.71%
3 Years
298.35%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ARGX315.324.77001.54
AAPL146.730.88000.60
GOOG2 837.9219.15000.68
MSFT299.791.21000.41
XOM57.131.92003.48
WFC48.060.98002.08
JNJ165.611.68001.02
FB346.132.92000.85
GE103.565.02005.09
JPM161.305.39003.46
Financial StrengthValueIndustryS&P 500US Markets
11.20
11.70
0.00
0.00
-251.90
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-69.00
-67.90
-494.80
-44.05
RevenueValueIndustryS&P 500US Markets
481.64M
9.37
79.03
60.62
Earnings HistoryEstimateReportedSurprise %
Q02 2021-3.381.98158.58
Q01 2021-3.14-0.8174.20
Q04 2020-2.89-4.20-45.33
Q03 2020-2.80-3.96-41.43
Q02 2020-2.55-3.15-23.53
Q01 2020-1.88-2.06-9.57
----
----
Earnings Per EndEstimateRevision %Trend
9/2021 QR-4.48-2.99Negative
12/2021 QR-4.840.62Positive
12/2021 FY-7.8239.75Positive
12/2022 FY-16.27-3.90Negative
Next Report Date28th Oct 2021
Estimated EPS Next Report-4.48
Estimates Count8
EPS Growth Next 5 Years %35.00
Volume Overview
Volume53.20K
Shares Outstanding51.44M
Shares Float51.40M
Trades Count1.24K
Dollar Volume63.17M
Avg. Volume179.24K
Avg. Weekly Volume302.86K
Avg. Monthly Volume210.90K
Avg. Quarterly Volume151.26K

argenx SE (NASDAQ: ARGX) stock closed at 310.55 per share at the end of the most recent trading day (a -1.84% change compared to the prior day closing price) with a volume of 215.90K shares and market capitalization of 16.22B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 188 people. argenx SE CEO is Tim Van Hauwermeiren.

The one-year performance of argenx SE stock is 28.71%, while year-to-date (YTD) performance is 5.6%. ARGX stock has a five-year performance of %. Its 52-week range is between 238.58 and 382.15, which gives ARGX stock a 52-week price range ratio of 53.45%

argenx SE currently has a PE ratio of -62.90, a price-to-book (PB) ratio of 5.77, a price-to-sale (PS) ratio of 33.40, a price to cashflow ratio of 57.40, a PEG ratio of 2.32, a ROA of -12.85%, a ROC of -15.08% and a ROE of -14.82%. The company’s profit margin is -44.05%, its EBITDA margin is -67.90%, and its revenue ttm is $481.64 Million , which makes it $9.37 revenue per share.

Of the last four earnings reports from argenx SE, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-4.48 for the next earnings report. argenx SE’s next earnings report date is 28th Oct 2021.

The consensus rating of Wall Street analysts for argenx SE is Strong Buy (1.21), with a target price of $363, which is +14.71% compared to the current price. The earnings rating for argenx SE stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

argenx SE has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

argenx SE has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.29, ATR14 : 9.25, CCI20 : -136.66, Chaikin Money Flow : -0.23, MACD : -1.43, Money Flow Index : 20.12, ROC : -11.42, RSI : 40.76, STOCH (14,3) : 1.28, STOCH RSI : 0.00, UO : 42.12, Williams %R : -98.72), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of argenx SE in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
10 (83.33 %)
9 (81.82 %)
9 (81.82 %)
Moderate Buy
1 (8.33 %)
1 (9.09 %)
1 (9.09 %)
Hold
1 (8.33 %)
1 (9.09 %)
1 (9.09 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.21
Strong Buy
1.23
Strong Buy
1.23

argenx SE

argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.

CEO: Tim Van Hauwermeiren

Telephone: +31 763030488

Address: Willemstraat 5, Breda 4811 AH, , NL

Number of employees: 188

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

54%46%

Bearish Bullish

67%33%

News

Stocktwits